✨ Medicines Distribution Consent
14 APRIL 2011 NEW ZEALAND GAZETTE, No. 51 1185
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Listerine Total Care Antiseptic Mouthwash, Clean Mint Flavour
Active Ingredients:
- Benzoic acid 0.12%w/v
- Cineole 0.092%w/v
- Ethanol 18.096%w/v
- Sodium fluoride 0.0221%w/v
- Thymol 0.064%w/v
- Zinc chloride 0.09%w/v
Dosage Form: Mouthwash
New Zealand Sponsor: Johnson & Johnson (New Zealand) Limited
Manufacturer: IDS Manufacturing Limited, Pathumthani, Thailand
Product: Tasigna
Active Ingredient: Nilotinib hydrochloride monohydrate 165.45mg equivalent to nilotinib anhydrous free base 150mg
Dosage Form: Capsule
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Novartis Pharma Stein AG, Stein, Switzerland
Product: Your Pharmacy Double Strength Paracetamol Suspension
Active Ingredient: Paracetamol 4.167%w/w
Dosage Form: Oral suspension
New Zealand Sponsor: Orion Laboratories (NZ) Limited
Manufacturer: PSM Healthcare Limited trading as API Consumer Brands, Auckland, New Zealand
Product: Your Pharmacy Pain Relief
Active Ingredients:
- Codeine phosphate hemihydrate 10mg
- Paracetamol 500mg
Dosage Form: Tablet
New Zealand Sponsor: Orion Laboratories (NZ) Limited
Manufacturer: PSM Healthcare Limited trading as API Consumer Brands, Auckland, New Zealand
Dated this 7th day of April 2011.
MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2410
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Synflorix
Active Ingredients:
- Pneumococcal Polysaccharide type 1 1μg
- Pneumococcal Polysaccharide type 14 1μg
- Pneumococcal Polysaccharide type 18C 3μg
- Pneumococcal Polysaccharide type 19F 3μg
- Pneumococcal Polysaccharide type 23F 1μg
- Pneumococcal Polysaccharide type 4 3μg
- Pneumococcal Polysaccharide type 5 1μg
- Pneumococcal Polysaccharide type 6B 1μg
- Pneumococcal Polysaccharide type 7F 1μg
- Pneumococcal Polysaccharide type 9V 1μg
Dosage Form: Suspension for injection
New Zealand Sponsor: GlaxoSmithKline (NZ) Limited
Manufacturers: - GlaxoSmithKline Biologicals SA, Rixensart, Belgium
- GlaxoSmithKline Biologicals SA, Wavre, Belgium
Dated this 7th day of April 2011.
MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).
go2412
Next Page →
✨ LLM interpretation of page content
🏥 Consent to Distribution of New Medicines
🏥 Health & Social Welfare7 April 2011
Medicines Act 1981, Listerine Total Care, Tasigna, Your Pharmacy Paracetamol, Your Pharmacy Pain Relief
- MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health
🏥 Consent to Distribution of a New Medicine
🏥 Health & Social Welfare7 April 2011
Medicines Act 1981, Synflorix
- MARK JACOBS, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation, Ministry of Health
NZ Gazette 2011, No 51